Pegaspargase: A Review in Acute Lymphoblastic Leukaemia

被引：96

作者：

Heo, Young-A ^{[1
]}

Syed, Yahiya Y. ^{[1
]}

Keam, Susan J. ^{[1
]}

机构：

[1] Springer, Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS | 2019年 / 79卷 / 07期

关键词：

GLYCOL-CONJUGATED ASPARAGINASE; ESCHERICHIA-COLI ASPARAGINASE; COST-MINIMIZATION ANALYSIS; PEGYLATED-ASPARAGINASE; INTRAMUSCULAR PEGASPARGASE; 1ST-LINE TREATMENT; ALLERGIC REACTIONS; PEG-ASPARAGINASE; HIGH-RISK; CHILDREN;

D O I：

10.1007/s40265-019-01120-1

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pegaspargase (Oncaspar((R))), a pegylated form of native Escherichia coli-derived l-asparaginase (hereafter referred as E. colil-asparaginase), is indicated in the USA and EU for the treatment of acute lymphoblastic leukaemia (ALL) as a component of multi-agent chemotherapy in paediatric and adult patients. Relative to E. colil-asparaginase, pegaspargase has a prolonged circulation time, thereby offering less frequent administration. Moreover, pegylation of E. colil-asparaginase may diminish the immunogenicity of the enzyme. Based on extensive evidence, intramuscular (IM) or intravenous (IV) administration of pegaspargase as a component of a multi-agent chemotherapy is an effective first-line treatment for paediatric and adult patients with ALL, as well as for the treatment of paediatric and adult patients with ALL and hypersensitivity to E. colil-asparaginase. Pegaspargase had a manageable tolerability profile in paediatric and adult patients with newly diagnosed ALL, with the most commonly occurring adverse events being generally consistent to that seen with E. colil-asparaginase. Pegaspargase treatment in patients with relapsed ALL and hypersensitivity to E. colil-asparaginase had a similar tolerability profile to that observed in patients with newly diagnosed ALL. Given the potentially reduced immunogenicity and more convenient dosage regimen over E. colil-asparaginase, pegaspargase remains an important and effective treatment option for paediatric and adult patients with ALL, including those with hypersensitivity to E. colil-asparaginase.

引用

页码：767 / 777

页数：11

共 39 条

[1] Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review [J].

Abbott, Lesleigh S. ;

Zakova, Maria ;

Shaikh, Furqan ;

Shewaramani, Nisha ;

Punnett, Angela ;

Dupuis, L. Lee .

PEDIATRIC DRUGS, 2015, 17 (04) :315-321

[2] Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol Escherichia coli L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4 [J].

Angiolillo, Anne L. ;

Schore, Reuven J. ;

Devidas, Meenakshi ;

Borowitz, Michael J. ;

Carroll, Andrew J. ;

Gastier-Foster, Julie M. ;

Heerema, Nyla A. ;

Keilani, Taha ;

Lane, Ashley R. ;

Loh, Mignon L. ;

Reaman, Gregory H. ;

Adamson, Peter C. ;

Wood, Brent ;

Wood, Charlotte ;

Zheng, Hao W. ;

Raetz, Elizabeth A. ;

Winick, Naomi J. ;

Carroll, William L. ;

Hunger, Stephen P. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (34) :3874-U276

[3]

[Anonymous], 2015, BLOOD, DOI DOI 10.1182/blood.V126.23.80.80

[4]

Asselin BL, 1999, ADV EXP MED BIOL, V457, P621

[5] A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia:: a Children's Cancer Group study [J].

Avramis, VI ;

Sencer, S ;

Periclou, AP ;

Sather, H ;

Bostrom, BC ;

Cohen, LJ ;

Ettinger, AG ;

Ettinger, LJ ;

Franklin, J ;

Gaynon, PS ;

Hilden, JM ;

Lange, B ;

Majlessipour, F ;

Mathew, P ;

Needle, M ;

Neglia, J ;

Reaman, G ;

Holcenberg, JS .

BLOOD, 2002, 99 (06) :1986-1994

[6] THE COST-EFFECTIVENESS OF PEGASPARGASE FOR FIRST-LINE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKAEMIA: A COST-UTILITY ANALYSIS [J].

Basu, S. ;

Lin, P. L. ;

Saha, V .

VALUE IN HEALTH, 2017, 20 (09) :A444-A444

[7] Severe pegaspargase hypersensitivity reaction rates (grade 3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials [J].

Burke, Michael J. ;

Devidas, Meenakshi ;

Maloney, Kelly ;

Angiolillo, Anne ;

Schore, Reuven ;

Dunsmore, Kimberly ;

Larsen, Eric ;

Mattano, Len A., Jr. ;

Salzer, Wanda ;

Winter, Stuart S. ;

Carroll, William ;

Winick, Naomi J. ;

Loh, Mignon L. ;

Raetz, Elizabeth ;

Hunger, Stephen P. ;

Bleyer, Archie .

LEUKEMIA & LYMPHOMA, 2018, 59 (07) :1624-1633

[8]

De Abrew KG, 2016, BRIT J HAEMATOL, V173, P103

[9] COST-MINIMIZATION ANALYSIS OF PEGASPARGASE AND NATIVE E. COLI ASPARAGINASE TO TREAT CHILDREN AND ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN BELGIUM [J].

Delattre, C. ;

Lecureuil, C. ;

Staginnus, U. ;

Pramanik, A. ;

Robbins, S. .

VALUE IN HEALTH, 2016, 19 (07) :A590-A590

[10] FDA drug approval summary:: Pegaspargase (Oncaspar ®) for the first-line treatment of children with acute lymphoblastic leukemia (ALL) [J].

Dinndorf, Patricia Anne ;

Gootenberg, Joseph ;

Cohen, Martin H. ;

Keegan, Patricia ;

Pazdur, Richard .

ONCOLOGIST, 2007, 12 (08) :991-998

← 1 2 3 4 →